Mondo Visione  Jul 23  Comment 
Nasdaq (Nasdaq:NDAQ) today announced that BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), will become a component of the NASDAQ-100 Index® (Nasdaq:NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq:NDXE) and the NASDAQ-100 Ex-Technology Index...
Motley Fool  Jul 20  Comment 
Orphan drug maker BioMarin has been a terrific stock for long-term investors, but is its pipeline strong enough to continue to propel the stock higher?
TheStreet.com  Jul 20  Comment 
BOSTON ( TheStreet) -- Biotech investors, circle Nov. 23 and Nov. 24 on your calendars. Use a thick, black marker. These appear to be the tentative dates chosen by the U.S. Food and Drug Administration to convene an advisory panel for the...
FierceBiotech  Jul 14  Comment 
Sarepta, jockeying with rival BioMarin to commercialize a treatment for Duchenne muscular dystrophy, is looking to buy up complementary assets to fortify its position. But the company's better-funded competitor believes its long history in rare...
TheStreet.com  Jul 10  Comment 
NEW YORK (TheStreet) -- Shares of BioMarin Pharmaceutical are up by 0.30% to $140.55 in early afternoon trading on Friday. BioMarin Pharmaceutical is a Novato, Calf.-based biotech company that develops and commercializes pharmaceuticals for a...
Market Intelligence Center  Jul 10  Comment 
BioMarin Pharmaceutical (BMRN) is an excellent choice for either a diagonal spread or a covered call expiring in Oct. '15 at the $140.00 level according to MarketIntelligenceCenter.com’s patented algorithms. A covered call on BioMarin...
FiercePharma  Jul 9  Comment 
The first half of 2015 is over and done, and as companies prep their earnings releases, we're looking at a different sort of scorecard: the one filled out by investors. In the realm of stock performance, some big drugmakers delivered big gains...
TheStreet.com  Jul 8  Comment 
NEW YORK (TheStreet) -- BoMarin Pharmaceutical had its price target raised to $155 from $145 by analysts at RBC Capital Markets with an "outperform" rating. The company develops and commercializes pharmaceuticals for serious diseases and...
FierceBiotech  Jun 29  Comment 
Sarepta, ending a protracted process that may have cost its last CEO his job, submitted its treatment for Duchenne muscular dystrophy to the FDA, setting the stage for a possible approval early next year.
TheStreet.com  Jun 22  Comment 
NEW YORK (TheStreet) -- Shares of BioMarin Pharmaceutical were gaining 0.2% to $138.17 on light trading volume on Monday afternoon. On Wednesday, analyst firm SunTrust Robinson Humphrey increased its price target for the biotechnology company...


BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.



BioMarin competes with companies like:


  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki